Fabry disease: overall effects of agalsidase alfa treatment. - Wikidata - awgldk - TriplyDB

Fabry disease: overall effects of agalsidase alfa treatment.

Fabry disease: overall effects of agalsidase alfa treatment.

http://www.wikidata.org/entity/Q45192336

about

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.Fabry disease and the skin: data from FOS, the Fabry outcome survey.Study of urinary proteomes in Anderson-Fabry disease.Enzyme replacement therapy for Fabry disease: some answers but more questions Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease Update on role of agalsidase alfa in management of Fabry disease.Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A The heart in Anderson-Fabry disease and other lysosomal storage disorders.Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Novel therapeutic targets for the treatment of Fabry disease.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.Early therapeutic intervention in females with Fabry disease?Substrate reduction therapy.Agalsidase alfa and kidney dysfunction in Fabry disease.Fabry disease in children and the effects of enzyme replacement treatment.Fabry disease: Evidence for a regional founder effect of the GLA gene mutation 30delG in Brazilian patients.Fabry disease: a review of current management strategies.Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia.Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease.Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity.Subclinical optic neuropathy in Fabry disease.[Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study.Shunt volume dynamics in stroke patients with patent foramen ovale.Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.

P2860

Q21004071-4C95F334-21BC-4CF3-9076-2924A9711467 Q24200877-0BA54023-2C48-4894-B1A4-27409AA6F55A Q24235483-D6C1C1FE-F662-4134-8C16-977CDEB57308 Q26471010-46793633-74C5-44EC-BC38-FF4BC2A18C9D Q31055371-C96A2E0E-6ABF-4304-B318-A199C0A16F83 Q31116015-54B6C4E6-8E15-4C92-9E7A-F8930F25A26B Q33721228-212BEA13-2057-46FF-A093-F038BF056514 Q34703815-141B60C6-9BEE-4E82-8A23-646BA2F63816 Q34794444-8ADC3121-5033-40E5-A852-1E5DF44C9384 Q34883178-D699EF47-3232-4439-BC6E-73BF0FCEA4D2 Q35009083-CE185E77-D2CF-43AA-B52C-F011D36F68B4 Q35771337-A25475E6-E28E-4189-83FC-769F090A68CB Q35773435-86E10FA8-0D38-4D6B-94E6-635A8A875C3A Q35795427-051C09B1-4241-4FCA-8FDA-592020BB9E34 Q36105190-60B4896E-9CB9-4029-9D94-15BD2F6A60F7 Q36571559-13E975A2-CC6F-4D58-9D15-52C5F766B9F9 Q36590934-DF18A474-973B-43CA-AEA3-A2CFDBFE6BCB Q36596408-B3C2C4F6-CA4A-4EDE-B0F0-BC162F6D5DFF Q36822452-ADA29D71-B337-4737-B472-6747AE53D352 Q36995447-4E3CA9B0-2A3C-4FD2-860C-D0EF6B3CD35D Q37029946-0CFC9564-6FC5-480A-BFF6-7A0FE07B68ED Q37109593-1835BF1D-6964-43C0-8F8A-7458FFA3EF74 Q37109597-3579804C-786F-4426-B471-420CD254B8FD Q37109614-D55B96F7-3F92-4276-80C7-827E6D0CDD74 Q37182010-DC72D5F9-D045-45B6-A27C-526C749BC4DF Q37350401-6C272492-316A-45EC-8144-CA68527CC85C Q37434242-D8791E9E-788C-43FC-9835-CFCA476C7FBD Q37775790-52EF9BF7-2658-428E-981F-629B4A71A082 Q37994740-B6FCB5B5-2408-4A17-8BF0-FB1943319827 Q38184922-9735195B-D104-48F5-84CF-1E46A94960F3 Q39782009-2319ED05-9870-4024-9DE5-FD79635B3DC9 Q41172322-B684B5E3-853B-47A3-BB92-59CC486609B4 Q41543943-7CB4407E-C420-4E6B-9F87-64512E805E62 Q43255977-AAB4FFDF-6264-440C-B66A-188CCBDF5D24 Q43271670-B212586D-C8D3-48E2-83AE-DE73E828F2FE Q43547536-1AF7B007-41FC-4015-B625-29C13FE117F5 Q44843689-B06193E6-8705-4F2E-8356-13B602C791AB Q46587509-ED7437CD-7026-4F43-B7E0-66D7333F6F0A Q46735411-E39B660B-C0DA-4145-929F-0F2E2E083A12 Q46881710-9E990922-007C-4748-944C-637F65D84B54

P2860

Fabry disease: overall effects of agalsidase alfa treatment.

http://www.wikidata.org/entity/Q45192336

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Fabry disease: overall effects of agalsidase alfa treatment.

@en

Fabry disease: overall effects of agalsidase alfa treatment.

@nl

type

label

Fabry disease: overall effects of agalsidase alfa treatment.

@en

Fabry disease: overall effects of agalsidase alfa treatment.

@nl

prefLabel

Fabry disease: overall effects of agalsidase alfa treatment.

@en

Fabry disease: overall effects of agalsidase alfa treatment.

@nl

P1433

Q45192336-5A316B7E-D168-4471-8BB5-F15C53713273

P1476

Q45192336-BF266F0A-C49C-4049-BEE1-C7E4F29D46F8

P2093

Q45192336-2EF5BEEB-C5F5-47E0-85E8-84DA6FB96EAE

Q45192336-46FCEB10-692B-45D2-828F-00CB399011E6

Q45192336-8810B1C5-AA63-4E3E-A812-3BCEBD81AFA8

Q45192336-9F457543-C28C-427D-8200-B24DBCF9A185

Q45192336-A3570315-9697-424D-AFED-37B1A9445F4D

Q45192336-A47FC32A-C5F6-4AA0-BBF7-A4154A0DADF0

Q45192336-B55F2701-2934-443E-B25E-7B2CD44C0ABD

Q45192336-CE43D785-4B1C-4D28-A0DF-FD645C98299D

Q45192336-D0B40BAC-B947-42C8-B32F-E6C72958E264

Q45192336-EF088EA7-0E8D-4454-9411-510A6E5D6F7E

P2860

Q45192336-12BAE962-A99B-468E-A2A7-3CC8C0827FF2

Q45192336-288A3D05-7C9E-4C99-9647-D7143D811B6B

Q45192336-4D131C72-07E6-4F80-8580-51414B736479

Q45192336-6D7658B7-80FD-4FE1-865A-1862002B5BD4

Q45192336-78FDF5E2-E7FA-411B-AE17-6A1C8CDDA55E

Q45192336-9CDC24BE-346B-472D-9DE6-B9D05D8F6755

Q45192336-CA6C126F-DFF5-450D-BBFF-B34A6278DCB8

Q45192336-D4E1B18B-2862-4BBC-ADC2-7C572EFB078F

Q45192336-FAA77111-3A46-4FC5-941C-F9EFD2022131

P304

Q45192336-D4147890-5275-4503-8182-E24B10DD0951

P31

Q45192336-7EC6C961-A0B8-45B9-8B9F-56613854D982

P356

Q45192336-2FD82C71-123D-4378-B8FB-6C40BA509E3A

P433

Q45192336-D2EDDAAA-4140-44A2-934D-F9A4C798B34B

P478

Q45192336-C28DC33B-2BB0-4365-8888-431A3DB70326

P50

Q45192336-D1162DF0-3DFE-4148-87CA-45D3B985CF26

P577

Q45192336-41939B5E-5309-40B9-8B39-7879F7D0AC1E

P5875

Q45192336-6F2EA1C2-839A-441F-8199-9116C3739ACC

P698

Q45192336-D73DE6F6-12D1-4DD3-BB90-321B7D8038C2

P356

J.1365-2362.2004.01424.X

P1433

European Journal of Clinical Investigation

P1476

Fabry disease: overall effects of agalsidase alfa treatment.

@en

P2093

A Gal

http://www.w3.org/2001/XMLSchema#string

A García de Lorenzo

http://www.w3.org/2001/XMLSchema#string

A Mehta

http://www.w3.org/2001/XMLSchema#string

C Kampmann

http://www.w3.org/2001/XMLSchema#string

F Dehout

http://www.w3.org/2001/XMLSchema#string

G Houge

http://www.w3.org/2001/XMLSchema#string

G Sunder-Plassmann

http://www.w3.org/2001/XMLSchema#string

M Beck

http://www.w3.org/2001/XMLSchema#string

R Ricci

http://www.w3.org/2001/XMLSchema#string

U Ramaswami

http://www.w3.org/2001/XMLSchema#string

P2860

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Prevalence of lysosomal storage disorders.

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

P304

838-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2004.01424.X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8122787

http://www.w3.org/2001/XMLSchema#string

P698

15606727

http://www.w3.org/2001/XMLSchema#string